S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.38%) $966.30
USD/EUR
(-0.36%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.36%) $91.45

实时更新: Aarti Drugs Limited [AARTIDRUGS.NS]

交易所: NSE 部门: Healthcare 工业: Drug Manufacturers—Specialty & Generic
最后更新时间3 May 2024 @ 17:59

0.36% INR 502.60

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 17:59):

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...

Stats
今日成交量 97 764.00
平均成交量 210 437
市值 46.21B
EPS INR0 ( 2024-04-13 )
下一个收益日期 ( INR0 ) 2024-07-18
Last Dividend INR1.000 ( 2023-02-08 )
Next Dividend INR0 ( N/A )
P/E 25.67
ATR14 INR1.356 (0.27%)

音量 相关性

長: -0.14 (neutral)
短: -0.62 (weak negative)
Signal:(42.814) Neutral

Aarti Drugs Limited 相关性

10 最正相关
BBL.NS0.955
RBLBANK.NS0.954
AIRAN.NS0.949
PGHH.NS0.944
KELLTONTEC.NS0.94
HPL.NS0.94
PREMEXPLN.NS0.939
SJVN.NS0.938
TWL.NS0.936
POLYCAB.NS0.934
10 最负相关
LTGILTBEES.NS-0.947
SINTEX.NS-0.924
RAJRILTD.NS-0.922
BOHRAIND.NS-0.92
RAJVIR.NS-0.911
BGLOBAL.NS-0.906
IRISDOREME.NS-0.906
OMAXE.NS-0.905
JPINFRATEC.NS-0.903
SRPL.NS-0.901

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Aarti Drugs Limited 相关性 - 货币/商品

The country flag -0.55
( weak negative )
The country flag -0.52
( weak negative )
The country flag -0.24
( neutral )
The country flag -0.67
( moderate negative )
The country flag -0.71
( moderate negative )
The country flag -0.61
( weak negative )

Aarti Drugs Limited 财务报表

Annual 2022
营收: INR27.16B
毛利润: INR8.28B (30.47 %)
EPS: INR17.96
FY 2022
营收: INR27.16B
毛利润: INR8.28B (30.47 %)
EPS: INR17.96
FY 2022
营收: INR24.89B
毛利润: INR5.04B (20.24 %)
EPS: INR22.12
FY 2021
营收: INR21.55B
毛利润: INR6.00B (27.86 %)
EPS: INR30.09

Financial Reports:

No articles found.

Aarti Drugs Limited Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
INR0
(N/A)
INR0
(N/A)
INR1.000
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)

Aarti Drugs Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.77 - low (58.39%) | Divividend Growth Potential Score: 3.35 - Decrease likely (33.07%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend INR0.150 2003-11-13
Last Dividend INR1.000 2023-02-08
Next Dividend INR0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 32 --
Total Paid Out INR15.88 --
Avg. Dividend % Per Year 0.23% --
Score 2.13 --
Div. Sustainability Score 4.77
Div.Growth Potential Score 3.35
Div. Directional Score 4.06 --
Next Divdend (Est)
(2024-10-31)
INR0 Estimate 0.00 %
Dividend Stability
0.08 Very Bad
Dividend Score
2.13
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2003 INR0 0.00%
2004 INR0 0.00%
2005 INR0 0.00%
2006 INR0 0.00%
2007 INR0 0.00%
2008 INR0 0.00%
2009 INR0 0.00%
2010 INR0 0.00%
2011 INR0 0.00%
2012 INR0 0.00%
2013 INR0 0.00%
2014 INR0 0.00%
2015 INR0 0.00%
2016 INR0 0.00%
2017 INR0 0.00%
2018 INR0.250 0.18%
2019 INR0.250 0.17%
2020 INR3.00 2.03%
2021 INR0 0.00%
2022 INR1.000 0.18%
2023 INR1.000 0.22%
2024 INR0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SUNTV.NS Dividend Knight 2023-08-22 Quarterly 19 1.94%
NAVNETEDUL.NS Dividend Junior 2023-08-07 Annually 22 1.10%
HPIL.NS Dividend Junior 2023-09-29 Annually 5 0.89%
CARERATING.NS Dividend Knight 2023-07-06 Semi-Annually 12 1.81%
ROSSELLIND.NS No Dividend Player 2023-07-20 Sporadic 12 0.12%
LFIC.NS Dividend Junior 2023-08-01 Annually 15 1.73%
GAEL.NS Dividend Junior 2023-08-25 Annually 23 0.27%
APOLLOPIPE.NS Dividend Junior 2023-09-15 Annually 3 0.07%
TCPLPACK.NS Dividend Junior 2023-07-27 Annually 7 1.08%
OFSS.NS Dividend Knight 2023-05-09 Annually 23 4.19%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06801.5008.6410.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.1501.5009.4410.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM8.411.0008.008.00[3 - 30]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
freeCashFlowPerShareTTM10.962.004.529.04[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.3221.0007.967.96[0.2 - 0.8]
operatingProfitMarginTTM0.1051.0009.919.91[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.77

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM25.471.0007.530[1 - 100]
returnOnEquityTTM0.1502.509.6410.00[0.1 - 1.5]
freeCashFlowPerShareTTM10.962.006.359.04[0 - 30]
dividendYielPercentageTTM0.2001.5004.990[0 - 0.4]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.3491.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.03801.000-1.5500[0.1 - 0.5]
Total Score3.35

Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。